|Table of Contents|

CXCL13 Involved in AR-Mediated Prostate Cancer CellXenograft Tumor Proliferation in vivo(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2018年03期
Page:
70-
Research Field:
·生命科学·
Publishing date:

Info

Title:
CXCL13 Involved in AR-Mediated Prostate Cancer CellXenograft Tumor Proliferation in vivo
Author(s):
Tian Qian; Cao Runyi; Wang Fangfang; Dong Jiajie; Ke Min; Lu Shan; Liu Ping
School of Life Sciences,Nanjing Normal University,Jiangsu Key Laboratory for Molecular and Medical Biotechnology,Nanjing 210023,China
Keywords:
CXCL13; AR-N; ETS-1; Cyclin B1; cell proliferation; prostate cancer
PACS:
Q291
DOI:
10.3969/j.issn.1001-4616.2018.03.012
Abstract:
As one of AR-targeted genes,it’s been reported that CXCL13 is involved in AR-mediated regulations of cell growth and proliferation in prostate cancer(PCa)cells. In this study,it’s further demonstrated that CXCL13 promotes prostate cancer cell proliferation in vivo,which is regulated by AR in xenograft tumor models established by CWR22Rv1 cells in nude mice. 20 male nude mice were randomly divided into 4 groups for subcutaneous injections with control CWR22Rv1 cells,CWR22Rv1 cells overexpressing AR,CWR22Rv1 cells knocking down CXCL13(with siCXCL13),or CWR22Rv1 cells overexpressing AR together with knocking down CXCL13. The knock-down of CXCL13 in vivo is performed via intratumoral injection with siCXCL13 every 3 d for 3 times. After tumors grown to 30 d,the differences of tumor growth among groups are analyzed by observing tumor morphology,measuring tumor size and weighting body weight of mice. Furthermore,western blot and immunohistochemistry are used to detect the expression of AR,CXCL13,ETS-1,Cyclin B1 and Snail. All in vivo data here are consistent with the conclusion we obtained in vitro in prostate cancer cell lines,suggesting that CXCL13 is involved in AR-mediated regulations of cell growth and proliferation in PCa cells in vivo.

References:

[1] 孙颖浩. 我国前列腺癌的研究现状[J]. 中华泌尿外科杂志,2004,25(2):77-80.
[2]刁鑫伟. 前列腺癌增殖和凋亡与雄激素受体表达的相关性研究[D]. 重庆:第三军医大学,2004.
[3]姜涛,李先承,宋希双,等. 雄激素受体在前列腺癌中表达和意义的探讨[J]. 中国男科学杂志,2005,19(6):29-32.
[4]ANTONARAKIS E S,LU C,WANG H,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer[J]. New England journal of medicine,2014,371(11):1028.
[5]RUPPRECHT T A,KOEDEL U,ANGELE B,et al. Cytokine CXCL13—a possible early CSF marker for neuroborreliosis[J]. Nervenarzt,2006,77(4):470-473.
[6]SINGH S,SINGH R,SHARMA P K,et al. Serum CXCL13 positively correlates with prostatic disease,prostate-specific antigen and mediates prostate cancer cell invasion,integrin clustering and cell adhesion[J]. Cancer letters,2009,283(1):29.
[7]EL HAIBI C P,SHARMA P K,SINGH R,et al. PI3Kp110-,Src-,FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells[J]. Molecular cancer,2010,9(1):85.
[8]WEDEL S A,RADITCHEV I N,JONES J,et al. CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer[J]. Molecular medicine reports,2008,1(2):257.
[9]KAKINUMA T,HWANG S T. Chemokines,chemokine receptors,and cancer metastasis[J]. Journal of leukocyte biology,2006,79(4):639-51.
[10]RODRíGUEZ-FRADE J M,MARTíNEZ-A C,MELLADO M. Chemokine signaling defines novel targets for therapeutic intervention[J]. Mini reviews in medicinal chemistry,2005,5(9):781-789.
[11]VAN DERCAPPELLEN J,VAN DAMME J,STRUYF S. The role of CXC chemokines and their receptors in cancer.[J]. Cancer letters,2008,267(2):226.
[12]RAZIS E,KALOGERAS K T,KOTOULA V,et al. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression[J]. Clinical breast cancer,2012,12(3):183-193.
[13]PANSE J,FRIEDRICHS K,MARX A,et al. Chemokine CXCL13 is overexpressed in the tumor tissue and in the peripheral blood of breast cancer patients[J]. British journal of cancer,2008,99(6):930.
[14]BISWAS S,SENGUPTA S,CHOWDHURY S R,et al. Erratum to:CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis[J]. Breast cancer research and treatment,2014,143(2):265.

Memo

Memo:
-
Last Update: 2018-11-19